Olanib 150 (Olaparib) 150 mg Tablets
16709₴
18028₴
-7%
Olanib 150 mg (Olaparib) is a tablet formulation of the PARP inhibitor used in targeted oncology treatment.
Manufacturer: Everest Pharmaceuticals. Each pack contains 120 tablets. It works by inhibiting poly (ADP-ribose) polymerase (PARP) enzymes, leading to the destruction of cancer cells with damaged DNA repair mechanisms (such as BRCA mutations).
Important Note:
Olanib tablets have different bioavailability compared to capsules. Do not substitute tablets for capsules on a mg-to-mg basis.
Indicated for the treatment of adult patients with:
- 🔹 Ovarian Cancer: Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- 🔹 Breast Cancer: Germline BRCA-mutated, HER2-negative metastatic breast cancer.
- 🔹 Pancreatic Cancer: Maintenance treatment for metastatic pancreatic cancer (gBRCA mutated).
- 🔹 Prostate Cancer: Metastatic castration-resistant prostate cancer with HRR gene mutations.
Packaging: 150 mg film-coated tablets.
⚠️ ADMINISTRATION PROTOCOL (Tablets):
- Recommended Dose: 300 mg taken twice daily.
- Per Dose: Take 2 tablets (150 mg each) in the morning and 2 in the evening.
- Total Daily Dose: 600 mg.
- Food Intake: Can be taken with or without food.
- Administration: Swallow tablets whole. Do not chew, crush, or split.
- Hypersensitivity to Olaparib.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
- Severe renal or hepatic impairment.
Common adverse reactions include:
- 🩸 Blood: Anemia (low hemoglobin), neutropenia, thrombocytopenia. Monthly blood tests are required.
- 📉 Digestive: Nausea, vomiting, fatigue, diarrhea, dysgeusia (taste changes).
- 🌀 Respiratory: Dyspnea (shortness of breath), cough.
- Patients should monitor for signs of fatigue and weakness.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!